Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance

被引：0
|
作者：
Lucien Torlot
Anna Jarzab
Johanna Albert
Ágnes Pók-Udvari
Arndt Stahler
Julian Walter Holch
Marco Gerlinger
Volker Heinemann
Frederick Klauschen
Thomas Kirchner
Jörg Kumbrink
Bernhard Küster
Andreas Jung
机构：
[1] Ludwig-Maximilians-University (LMU),Institute of Pathology
[2] German Cancer Consortium (DKTK),Chair or Proteomics and Bioanalytics
[3] Technical University of Munich,Department of Hematology, Oncology, and Cancer Immunology
[4] Charité - Universitätsmedizin Berlin,Department of Medicine III
[5] Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin,Comprehensive Cancer Center Munich (CCCM)
[6] German Cancer Consortium (DKTK),Translational Oncogenomics Lab
[7] LMU Hospital,Barts Cancer Institute
[8] LMU Hospital,Gastrointestinal Cancer Unit
[9] The Institute of Cancer Research,undefined
[10] Queen Mary University of London,undefined
[11] St Bartholomew’s Hospital,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词：
Colorectal cancer; EPHA2; Cetuximab resistance; Molecular oncology; Proteomics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：669 / 682
页数：13
相关论文
共 50 条
  • [21] Proteomics profiling of colorectal cancer progression identifies PLOD2 as a potential therapeutic target
    Shao, Yingkuan
    Xu, Kailun
    Zheng, Xi
    Zhou, Biting
    Zhang, Xiuli
    Wang, Lin
    Sun, Yaoting
    Li, Dan
    Chen, Ting
    Wang, Jian
    Yu, Shaojun
    Sun, Lifeng
    Xu, Xiaoming
    Dai, Shaozhi
    Gao, Huanhuan
    Ruan, Guan
    Liu, Wei
    Cai, Xue
    Zhu, Tiansheng
    Qi, Lina
    Chen, Jiani
    Hu, Wangxiong
    Weng, Xingyue
    Zhu, Yi
    Xiang, Xueping
    Hu, Zhiyuan
    Li, Jinfan
    Chen, Lirong
    Shao, Jimin
    Zheng, Shu
    Guo, Tiannan
    CANCER COMMUNICATIONS, 2022, 42 (02) : 164 - 169
  • [22] Colorectal cancer stem cell: a potential therapeutic target
    Tao, Haiying
    Zhu, Yongliang
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (12): : 833 - 838
  • [23] Colorectal cancer stem cell: a potential therapeutic target
    Haiying Tao
    Yongliang Zhu
    Clinical and Translational Oncology, 2011, 13 : 833 - 838
  • [24] RETRACTED ARTICLE: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma
    Mark S Duxbury
    Hiromichi Ito
    Michael J Zinner
    Stanley W Ashley
    Edward E Whang
    Oncogene, 2004, 23 : 1448 - 1456
  • [25] Retraction Note: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma
    Mark S. Duxbury
    Hiromichi Ito
    Michael J. Zinner
    Stanley W. Ashley
    Edward E. Whang
    Oncogene, 2023, 42 : 938 - 938
  • [26] Evaluation of EphA2 as a therapeutic target for redirected T-cell killing by DART® bispecific molecules
    Fieger, Claudia B.
    Shah, Kalpana
    Chichili, Gurunadh
    Li, Jonathan
    Son, Thomas
    Hooley, Jeffrey
    Chen, Francine
    Gorlatov, Sergey
    Burke, Steve
    Ciccarone, Valentina
    Alderson, Ralph
    Loo, Deryk
    Johnson, Syd
    Bonvini, Ezio
    Moore, Paul
    CANCER RESEARCH, 2016, 76
  • [27] EPHA2 receptor is involved in in vivo acquired resistance to anti-epidermal growth factor receptor (EGFR) treatment in metastatic colorectal cancer
    Martini, G.
    Belli, V.
    Vitiello, P. P.
    Troiani, T.
    Cardone, C.
    Napolitano, S.
    Matrone, N.
    Sforza, V.
    Savastano, B.
    Renato, F.
    Morgillo, F.
    Della Corte, C. M.
    Ciardiello, D.
    Giunta, E. F.
    De Falco, V.
    Zanaletti, N.
    Vitale, P.
    Ciardiello, F.
    Martinelli, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] TAK-901, a novel EPHA2 inhibitor as a therapeutic strategy against prostate cancer
    Liu, Shanhui
    Fu, Shengjun
    Wu, Xuewu
    Wu, Shan
    Zhao, Youli
    Wu, Xinyue
    Yan, Liting
    Lu, Jianzhong
    Li, Lanlan
    Tao, Yan
    CELLULAR SIGNALLING, 2025, 131
  • [29] Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma
    Ruan, Hailong
    Li, Sen
    Bao, Lin
    Zhang, Xiaoping
    ONCOGENE, 2020, 39 (38) : 6113 - 6128
  • [30] Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma
    Hailong Ruan
    Sen Li
    Lin Bao
    Xiaoping Zhang
    Oncogene, 2020, 39 : 6113 - 6128
12345